BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 1746913)

  • 1. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
    Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
    Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
    Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
    Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
    Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
    Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
    Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA; Holden SA; Ara G; Northey D
    Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of etanidazole with cyclophosphamide and platinum complexes.
    Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
    Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents.
    Fingert HJ; Chang JD; Pardee AB
    Cancer Res; 1986 May; 46(5):2463-7. PubMed ID: 3084068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA; Holden SA; Herman TS; Frei E
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
    Teicher BA; Waxman DJ; Holden SA; Wang YY; Clarke L; Alvarez Sotomayor E; Jones SM; Frei E
    Cancer Res; 1989 Sep; 49(18):4996-5001. PubMed ID: 2504483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity, radiosensitization, antitumor activity, and interaction with hyperthermia of a Co(III) mustard complex.
    Teicher BA; Abrams MJ; Rosbe KW; Herman TS
    Cancer Res; 1990 Nov; 50(21):6971-5. PubMed ID: 2208163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa.
    Dezube BJ; Eder JP; Pardee AB
    Cancer Res; 1990 Nov; 50(21):6806-10. PubMed ID: 2119882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide.
    Teicher BA; Holden SA; Rose CM
    J Natl Cancer Inst; 1985 Dec; 75(6):1129-33. PubMed ID: 3934448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.